The European Union has approved Lecanemab, a groundbreaking drug developed by Biogen to slow down the progression of Alzheimer’s disease. Manufactured in Luterbach, Switzerland, it targets harmful amyloid proteins in the brain, improving cognitive function in early-stage patients. Despite some…

The European Medicines Agency (EMA) has granted its first approval for a treatment targeting the underlying processes of Alzheimer’s disease. The antibody Lecanemab is authorized for individuals with mild cognitive impairment or early-stage dementia. Produced by Biogen’s Swiss branch, this…